These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3111909)

  • 1. Freeze-dried activated substrate for factor VIII assays.
    Margolis J
    Dev Biol Stand; 1987; 67():163-7. PubMed ID: 3111909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyophilised plasmas for one-stage determination of factor VIII.
    Sikorová J; Vorlová Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):906-13. PubMed ID: 6162757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
    Kessler CM; Bernstein Z; Ghesani S; Shamsipour Z; Frances C; Zucker ML; LaDuca FM
    Am J Hematol; 1996 Mar; 51(3):181-5. PubMed ID: 8619397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
    Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T
    Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of phospholipid reagents used in coagulation I: some general properties and their sensitivity to factor VIII.
    Barrowcliffe TW; Gray E
    Thromb Haemost; 1981 Oct; 46(3):629-33. PubMed ID: 6797093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay.
    Nougier C; Sobas F; Nguyen TK; Carage ML; Lienhart A; Négrier C
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):151-4. PubMed ID: 21192255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
    Rosén S; Andersson M; Blombäck M; Hägglund U; Larrieu MJ; Wolf M; Boyer C; Rothschild C; Nilsson IM; Sjörin E
    Thromb Haemost; 1985 Dec; 54(4):818-23. PubMed ID: 3937277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers.
    Bakaltcheva I; O'Sullivan AM; Hmel P; Ogbu H
    Thromb Res; 2007; 120(1):105-16. PubMed ID: 16962645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trypsin clotting time (K-test) in hemophilia A and in hemophilia B1.
    Girolami A; Dal Bo Zanon R; Procidano M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):863-71. PubMed ID: 6176512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial factor VIII deficient plasma: preparation using monoclonal antibodies and its use in one stage coagulation assays.
    Hornsey VS; Waterston YG; Prowse CV
    J Clin Pathol; 1988 May; 41(5):562-7. PubMed ID: 3133400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A standardized method for measuring anti-F VIII: C inhibitors in haemophilia A by coagulation inhibition in agarose gel.
    Jorquera JI; Carmona E; Aznar JA; Peiró A; Sánchez-Cuenca JM
    Thromb Haemost; 1985 Aug; 54(2):377-80. PubMed ID: 3936211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preparation of an artificial reagent for the one-stage factor VIII assay.
    Nyman D
    Thromb Diath Haemorrh; 1970 May; 23(2):206-12. PubMed ID: 5426208
    [No Abstract]   [Full Text] [Related]  

  • 13. Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
    Scand J Haematol; 1980 Oct; 25(4):308-17. PubMed ID: 6782653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
    Allain JP
    Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
    [No Abstract]   [Full Text] [Related]  

  • 15. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
    Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
    Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method.
    Torita S; Suehisa E; Kawasaki T; Toku M; Takeo E; Tomiyama Y; Nishida S; Hidaka Y
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):185-9. PubMed ID: 21245748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of CS-2500 and BCS XP coagulation analyzers for Factor VIII and Factor IX one-stage clotting assays.
    Genc S; Aydin AF; Karaca E; Ömer B
    Int J Lab Hematol; 2019 Oct; 41(5):e124-e127. PubMed ID: 31034727
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pathogenesis and treatment of Willebrand's disease].
    Meili EO; Straub PW; Frick PG
    Schweiz Med Wochenschr; 1969 Dec; 99(50):1805-10. PubMed ID: 5311783
    [No Abstract]   [Full Text] [Related]  

  • 20. Equations for the calculation of factor VIII potencies from the results of parallel-line clotting-time assays.
    Kuwahara SS
    Haematologia (Budap); 1988; 21(2):91-8. PubMed ID: 3138167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.